Bixalomer

Summary

Bixalomer (CHEMBL4297202) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297202
Name	Bixalomer
Type	Small molecule
Max phase	3

Also known as: AMG-223, ASP-1585, Asp1585, ASP1585, Bixalomer, Bixalomere, Bixalomero, ILY-101, Ily101, ILY101, Kiklin, BIXALOMER

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE3	5
PHASE1	5
PHASE2	3
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00892749	PHASE3	COMPLETED	Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
NCT01017276	PHASE3	COMPLETED	A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis
NCT01057407	PHASE3	COMPLETED	A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
NCT01742585	PHASE3	COMPLETED	A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
NCT01742611	PHASE3	COMPLETED	Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
NCT00358046	PHASE2	UNKNOWN	Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia
NCT00505037	PHASE2	COMPLETED	A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
NCT02753894	PHASE2	COMPLETED	Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
NCT01115946	PHASE1	COMPLETED	A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Enalapril in Healthy Volunteers
NCT01115972	PHASE1	COMPLETED	A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy Volunteers
NCT01115985	PHASE1	COMPLETED	A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers
NCT01124747	PHASE1	COMPLETED	A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug
NCT02531204	PHASE1	COMPLETED	A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 Capsules
NCT01901107	Not specified	COMPLETED	Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients
NCT01903213	Not specified	COMPLETED	Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis
NCT02805348	Not specified	COMPLETED	Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).